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Abstract. 
 
The inherited neurodegenerative diseases 
caused by an expanded glutamine repeat share the 
pathologic feature of intranuclear aggregates or inclu-
sions (NI). Here in cell-based studies of the spinocere-
bellar ataxia type-3 disease protein, ataxin-3, we ad-
dress two issues central to aggregation: the role of 
polyglutamine in recruiting proteins into NI and the 
role of nuclear localization in promoting aggregation. 
We demonstrate that full-length ataxin-3 is readily re-
cruited from the cytoplasm into NI seeded either by a 
pathologic ataxin-3 fragment or by a second unrelated 
glutamine-repeat disease protein, ataxin-1. Experi-
ments with green fluorescence protein/polyglutamine 
fusion proteins show that a glutamine repeat is suffi-
cient to recruit an otherwise irrelevant protein into NI, 
and studies of human disease tissue and a 
 
Drosophila
 
 
transgenic model provide evidence that specific 
glutamine-repeatÐcontaining proteins, including 
TATA-binding protein and Eyes Absent protein, are 
recruited into NI in vivo. Finally, we show that nuclear 
localization promotes aggregation: an ataxin-3 frag-
ment containing a nonpathologic repeat of 27 
glutamines forms inclusions only when targeted to the 
nucleus. Our findings establish the importance of the 
polyglutamine domain in mediating recruitment and 
suggest that pathogenesis may be linked in part to the 
sequestering of glutamine-containing cellular proteins. 
In addition, we demonstrate that the nuclear environ-
ment may be critical for seeding polyglutamine aggre-
gates.
Key words: trinucleotide ¥ triplet repeat ¥ Machado-
Joseph disease ¥ neurodegeneration ¥ hereditary ataxia
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 trinucleotide repeat expansion is now known
to be the underlying genetic defect in a growing
number of neurodegenerative diseases. To date,
these include HuntingtonÕs disease, dentatorubral-pallido-
luysian atrophy, spinobulbar muscular atrophy, and five
forms of dominantly inherited spinocerebellar ataxia for
which a mutation has been identified, including types 1, 2,
3, 6, and 7 (for reviews see Paulson and Fischbeck, 1996;
Hackam et al., 1998). In each disease gene, a CAG repeat
expansion occurs within the protein coding region, result-
ing in an expanded polyglutamine repeat in the otherwise
unrelated disease proteins. Evidence supports a model of
disease in which polyglutamine expansion confers a toxic
gain-of-function property on the protein (Ross, 1997). This
novel neurotoxic property likely involves an increased
propensity for the disease protein to misfold and aggre-
gate. In glutamine-repeat diseases, a common manifesta-
tion of this misfolding and aggregation is the formation of
intranuclear inclusions (NI)
 
1
 
 of the disease protein (Lunkes
and Mandel, 1997; Davies et al., 1998). In many glutamine-
repeat diseases, NI have been found in neurons that are
known to be susceptible to the disease process, suggesting
that intranuclear aggregation is central to pathogenesis
(DiFiglia et al., 1997; Paulson et al., 1997
 
b
 
; Skinner et al.,
1997; Holmberg et al., 1998; Igarashi et al., 1998; Li et al.,
1998). Moreover, several glutamine-repeat disease pro-
teins are primarily cytoplasmic, yet nuclear inclusions are
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Abbreviations used in this paper:
 
 EYA, Eyes Absent protein; GFP,
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kidney; MJD, Machado-Joseph disease; NI, intranuclear inclusions; NLS,
nuclear localization signal; SCA, spinocerebellar ataxin; TBP, TATA-
binding protein.
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the major pathologic structure observed in these diseases,
suggesting that the nuclear environment enhances aggre-
gation.
The fact that NI are found only in select neurons despite
widespread expression of the various disease proteins sug-
gests that additional cell-specific factors influence the like-
lihood of polyglutamine aggregation in a given neuron.
Such factors may include the presence of a specific pro-
tease or proteases that cleave expanded polyglutamine
disease proteins. This processing event would liberate a
polyglutamine-containing fragment that is capable of en-
tering the nucleus and forming aggregates. In support of
this model, many transgenic and cell culture models of
polyglutamine disease have used polyglutamine-contain-
ing fragments of the disease protein that are particularly
potent at aggregating and causing neuronal dysfunction
and degeneration (Ikeda et al., 1996; Mangiarini et al.,
1996; Paulson et al., 1997
 
b
 
; Cooper et al., 1998; Merry et al.,
1998; Warrick et al., 1998). Although no specific protease
has yet been identified, it has been documented that many
of the polyglutamine disease proteins are substrates for
proteolytic processing (Goldberg et al., 1996; Miyashita
et al., 1997; Wellington et al., 1998). A working model for
aggregation in disease, then, is the seeding of aggregates
by proteolytic fragments followed by recruitment of the
full-length protein into inclusions.
NI are not pure aggregates of the pathologic poly-
glutamine-containing protein. Although the full array of
molecules comprising NI is still unknown, studies of hu-
man tissue and transgenic mice indicate that NI also con-
tain ubiquitin, components of the proteasome complex,
and certain molecular chaperones (Cummings et al., 1998;
Paulson, H.L., unpublished observations). Given the ap-
parent heterogeneous composition of NI, it is possible that
neuronal dysfunction is mediated in part through the re-
cruitment and sequestration of critical cellular proteins. A
favored model for the mechanism of aggregation is strong
noncovalent, intermolecular interactions between the poly-
glutamine domains of proteins, perhaps in the form of a
hydrogen-bonded Òpolar zipperÓ as proposed by Perutz
and colleagues (Perutz et al., 1994; Stott et al., 1995; an
alternative theory proposed by Kahlem et al., 1996, is
covalent cross-linking by transglutaminase). Given these
models, intracellular proteins that normally contain glu-
tamine-rich or pure polyglutamine domains might be re-
cruited into NI by virtue of their polyglutamine domains.
In an effort to understand disease pathogenesis, it is im-
portant to determine the extent to which cellular proteins
are recruited into NI, either through glutamine-dependent
or -independent mechanisms.
As a model for glutamine-repeat disease proteins we
have chosen to study ataxin-3, the defective gene product
in spinocerebellar ataxia type 3/Machado-Joseph disease
(SCA3/MJD), the most common dominantly inherited
ataxia (Matilla et al., 1995; Ranum et al., 1995; Schols et al.,
1995; Durr et al., 1996). SCA3/MJD is characterized by
selective neural degeneration within the deep basal gan-
glia, brainstem, cerebellum, and spinal cord, despite wide-
spread expression of mutant ataxin-3 throughout the brain
(Sachdev et al., 1982; Yuasa et al., 1986; Takiyama et al.,
1994; Paulson et al., 1997
 
a
 
). The gene product of the
 
MJD1
 
 gene, ataxin-3, is a novel protein of unknown func-
tion with a molecular mass of 
 
z
 
42 kD (Kawaguchi et al.,
1994). Its glutamine repeat lies near the COOH terminus,
where it is normally 12Ð40 glutamine residues in length
and is increased in disease to 55Ð84 residues. Studies of
ataxin-3 suggest that its subcellular localization is complex
and includes both cytoplasmic and nuclear localization
that vary depending upon the cell type and perhaps other
cellular factors (Paulson et al., 1997
 
a
 
; Wang et al., 1997;
Tait et al., 1998; Paulson, H.L., unpublished observations).
We demonstrated previously that a COOH-terminal
ataxin-3 fragment containing an expanded glutamine tract
forms perinuclear and nuclear inclusions in transfected
cells, whereas full-length expanded ataxin-3 does not (Paul-
son et al., 1997
 
b
 
). Here, we define the molecular determi-
nants driving recruitment of full-length disease protein
and other proteins into aggregates, and address the role of
the nuclear environment in promoting aggregation. We
show that polyglutamine plays an important role in medi-
ating recruitment of proteins into NI. The cell-based stud-
ies are supported by in vivo data from human disease tis-
sue and a 
 
Drosophila
 
 transgenic model which demonstrate
that specific glutamine-repeat proteins are recruited into
NI: TATA-binding protein (TBP) in SCA3/MJD tissue,
and the nuclear protein Eyes Absent (EYA) in 
 
Dro-
sophila
 
. Finally, in experiments with nuclear-targeted
ataxin-3, we present evidence that the nuclear environ-
ment promotes aggregate formation: an ataxin-3 fragment
with a nonpathologic repeat does not form inclusions
when expressed in the cytoplasm, but does so when it is
targeted to the nucleus.
 
Materials and Methods
 
Expression Constructs and Transfection
 
Fig. 1 shows the expression constructs used in this study. Ataxin-1 con-
structs were provided by H. Orr and E. Burright (Skinner et al., 1997).
GFP fusion proteins were provided by W. Strittmatter (Onodera et al.,
1997).
A myc or hemagglutinin (HA) epitope tag was placed at the NH
 
2
 
 ter-
minus of the normal and expanded ataxin-3 sequence using PCR with
primers that included a BamHI site to facilitate cloning into expression
vectors. Primers were: myc (5
 
9
 
-AGCGGATCCACAGCCATGGAACA-
GAAACTCATCTCTGAAGAGGATCTGGAGTCCATCTTCCAC-
GAG-3
 
9
 
) and HA (5
 
9
 
-AGCGGATCCACAGCCATGTACCCATAC-
GATGTTCCAGATTACGCTGAGTCCATCTTCCACGAG-3
 
9
 
). COOH-
terminal FLAG-epitope tagged constructs were generated by PCR with
a primer that contained an EcoRI site (5
 
9
 
-TGGAAGTGTGAAATA-
GACTGTCTGATGTTCCTGCTGCTACTGTTCATTATCCTTAAG-
ATG-3
 
9
 
). Ataxin-3 lacking the COOH terminus of the protein including
the glutamine repeat (MJD
 
D
 
288-354) was generated by PCR using a 3
 
9
 
primer that inserts two consecutive stop codons after an alanine residue
(Ala287) four amino acids proximal to the glutamine repeat. Truncated
ataxin-3 constructs consisting of the glutamine repeat and the remaining
COOH terminus were described previously (Paulson et al., 1997
 
b
 
). The
above ataxin-3 constructs were subcloned into pcDNA3 (Invitrogen,
Carlsbad, CA). Additional truncated constructs were tagged with a nu-
clear localization signal (NLS) by PCR and placed into the expression vec-
tor pAG-3. In this vector, the expressed protein is tagged at the COOH
terminus with a myc-hexahistidine epitope tag (Koppel et al., 1997). For
the NLS constructs we used the 5
 
9
 
 primer (5
 
9
 
-GGATCCACCATG-
CCCAAGAAGAAGCGGAAGGTCCGAGAAGCCTACTTTGAAA-
AACAG-3
 
9
 
) and the 3
 
9
 
 primer (5
 
9
 
-GCGGCCGCTCTGTCAGATA-
AAGTGTGAAGG-3
 
9
 
). Human embryonic kidney cells (HEK-293T)
were transfected by calcium phosphate as described previously (Paulson
et al., 1997
 
b
 
). For immunofluorescence, cells were subcultured onto col-
lagen-coated glass coverslips 24 h after transfection, and for Western blot-
ting cells were grown in 35-mm dishes for 36Ð48 h. 
Perez et al. 
 
Recruitment in Glutamine-Repeat Diseases
 
1459
 
The fly lines used in these studies were of genotypes 
 
gmr-GAL4
 
1
 
UAS-MJDtr-Q78(S)
 
, and 
 
dpp-GAL4
 
1
 
UAS-MJDtr-Q78(S)
 
,
 
 dpp-GAL4
 
1
 
UAS-eya-N/UAS-MJDtr-Q78(S)
 
, and 
 
dpp-GAL4
 
1
 
UAS-eya-C/UAS-MJDtr-
Q78(S)
 
. 
 
UAS-eya-N
 
 is an Eya COOH-terminal deletion construct contain-
ing amino acids 1Ð487 of the 
 
Drosophila
 
 type I EYA protein (see Bonini
et al., 1993). 
 
UAS-eya-C
 
 is an Eya NH
 
2
 
-terminal deletion construct con-
taining amino acids 1Ð34 fused to amino acids 449Ð760 of the type I pro-
tein. Fly tissue was stained for immunofluorescence and viewed by confo-
cal microscopy as described (Warrick et al., 1998).
 
Immunofluorescence and Microscopy
 
48 h after transfection, cells were prepared for immunofluorescence and
confocal microscopy. In brief, cells were washed once in PBS and fixed in
4% paraformaldehyde for 10 min. Cells were rinsed three times with PBS
and permeabilized for 10 min in 0.05% Triton X-100 in PBS. Coverslips
were then incubated in block buffer (2% goat serum, 0.05% Triton X-100
in PBS) for 30 min. Cells were incubated for 90 min at room temperature
with the following primary antibodies diluted in block buffer: 9E10 anti-
myc (1:100; Calbiochem, San Diego, CA), Y11 or 12CA5 anti-HA (1:1,000;
Santa Cruz Biotechnology, Santa Cruz, CA), affinity-purified anti-MJD
(1:1,000; Paulson et al., 1997
 
a
 
), M2 anti-FLAG (1:200; Eastman Kodak,
New Haven, CT), the anti-TBP Ab SI-1 (1:200; Santa Cruz Biotechnol-
ogy); the anti-TBP Ab N-12 (1:200; Santa Cruz Biotechnology), and anti-
EYA 10H6 raised to a conserved peptide domain of the 
 
Drosophila
 
 EYA
protein (1:10; Bonini et al., 1993). Coverslips were rinsed three times with
PBS and incubated with goat antiÐrabbit FITC (Jackson Laboratories,
West Grove, PA) and/or goat antiÐmouse rhodamine (Jackson Laborato-
ries), each at 1:1,000 in PBS for 90 min. Coverslips were rinsed three times
with PBS, once with deionized water and mounted on glass slides (Fisher
Scientific, Pittsburgh, PA) with vectashield (Vector Laboratories, Burlin-
game, CA). Standard epifluorescence was performed using an Olympus
IX70 microscope and digital images were captured directly into Adobe
Photoshop (V.4.0) using a Sony DKC-5000 camera. Confocal images were
obtained from a Leica TCS-NT laser confocal microscope (Heidelberg,
Germany) and images were processed in Adobe Photoshop.
 
Western Blots
 
Pelleted cells were washed in PBS and lysed in 2
 
3
 
 SDS sample buffer. Ly-
sates were sonicated and heated for 3 min at 90
 
8
 
C before electrophoresis
on 7.5 or 10% SDS-polyacrylamide gels. Gels were then transblotted to
PVDF membranes (DuPont NEN, Boston, MA) which were then washed
in PBST (0.05% Tween 20 in PBS) and blocked for 1 h in PBS containing
5% nonfat milk (Carnation, Glendale, CA). Blots were incubated in 9E10
(1:1,000), M2 (1:160), or Y11 (1:1,000) for 60 min, rinsed three times in
PBST, and incubated in 1:2,000 goat antiÐrabbit HRP (Santa Cruz Bio-
technology), or 1:4,000 goat antiÐmouse HRP (Jackson Laboratories) for
60 min and visualized using chemiluminescence (DuPont NEN) on Kodak
film. For human disease tissue, 75 
 
m
 
g of protein from SCA3/MJD pons
was lysed in 2
 
3
 
 SDS sample buffer, sonicated, and heated for 5 min at
90
 
8
 
C before electrophoresis on a 7.5% SDS-polyacrylamide gel. Transfer
of protein onto PVDF and washes were performed as described above.
Samples were run in parallel and blots were probed with antiÐataxin-3 an-
tisera (1:15,000) or the anti-TBP antibody SI-1 (1:500) for 60 min, the
blots were rinsed three times in PBST and incubated in 1:2,000 goat antiÐ
rabbit HRP for 60 min and visualized using chemiluminescence as de-
scribed. The blot probed with SI-1 was then washed in stripping buffer
(62.5 mM Tris-HCl, pH 6.8, 2% SDS, 100 mM 2-mercaptoethanol) at 50
 
8
 
C
for 30 min, rinsed several times in PBST, and chemiluminescence con-
firmed that there was no residual signal. This blot was then reprobed with
the anti-TBP antibody N-12 (1:500) and visualized as described above.
 
Immunohistochemistry
 
Immunohistochemical staining of human disease tissue was performed as
described previously (Paulson et al., 1997
 
a
 
) except that sections were not
counterstained with hematoxylin and, in the experiment shown in Fig. 9,
 
aÐe
 
, nickel enhancement of the peroxidase reaction was used. The SCA3/
MJD brain tissue used was from the case described earlier (Paulson et al.,
1997
 
a
 
); a tissue block from the midpontine region with abundant NI was
chosen for analysis. Sections from the rostral pons of a nondisease control
brain were immunostained, then processed and analyzed simultaneously.
Two different antibodies were used to detect TBP. The first, SI-1 (sc-273;
Santa Cruz Biotechnology), is a polyclonal antibody raised against full-
length TBP. The second, N-12 (sc-204; Santa Cruz Biotechnology), is a
polyclonal antibody raised against amino acids 12Ð29 of TBP, a region
that does not contain the polyglutamine domain of TBP. Western blot
analyses of lysates from normal and SCA3/MJD disease brain confirmed
that neither antibody cross-reacted with normal or expanded ataxin-3.
Moreover, immunofluorescence studies of transfected cells demonstrated
that nuclear aggregates formed by NLS-Q78-myc were not labeled with
anti-TBP antisera, indicating that the antibody does not cross-react with
an expanded polyglutamine repeat.
To estimate the percentage of NI positive for TBP, all immunostained
NI were counted in a sweep across the identical regions of adjacent SCA3/
MJD sections stained with antiÐataxin-3 antisera (Paulson et al., 1997
 
a
 
) or
with anti-TBP antisera SI-1 (Santa Cruz Biotechnology). All neurons with
a clearly discernible nucleus were scored for the presence or absence of
immunostained NI. 350Ð380 neurons were analyzed in each complete
sweep.
 
Quantification of Recruitment
 
To quantitate recruitment of ataxin-3 into ataxin-1 nuclear inclusions, we
Figure 1. Expression constructs used in this study. Some con-
structs contain an NH2-terminal HA, myc, or FLAG epitope tag
as indicated, whereas others have an NH2-terminal NLS and a
COOH-terminal myc tag. For the first eight constructs, the gray
region represents the NH2-terminal portion of ataxin-3 up to the
glutamine domain and the hatched region represents the COOH-
terminal 43 amino acids after the glutamine domain. Individual
nomenclature for the constructs is as follows: HA-MJD(27) and
HA-MJD(78), full-length ataxin-3 containing 27 or 78 glutamines
with NH2-terminal HA epitope tag; myc-MJD(27), full-length
ataxin-3 containing 27 glutamines with NH2-terminal myc epitope
tag; myc-MJD(78)-F, full-length ataxin-3 containing 78 gluta-
mines with NH2-terminal myc epitope tag and COOH-terminal
FLAG epitope tag; HA-Q78, NH2-terminal HA tagged truncated
ataxin-3 containing 12 amino acids NH2-terminal and 43 amino
acids COOH-terminal of the 78 glutamine residues; myc-
MJDD288-354, truncated ataxin-3 containing the first 287 amino
acids with an NH2-terminal myc tag; NLS-Q27-myc and NLS-
Q78-myc, COOH-terminal myc tagged, nuclear-targeted frag-
ment of ataxin-3 containing 12 amino acids NH2-terminal and 43
amino acids COOH-terminal of 27 or 78 glutamine residues;
GFP, GFP-Q19, GFP-Q35, or GFP-Q80, GFP either alone of in
fusion with 19, 35, or 80 glutamine residues; F-SCA1(30) and
F-SCA1(82), full-length ataxin-1 containing 30 or 82 glutamines
and an NH2-terminal FLAG epitope tag. 
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scored in random microscopic fields all cells that were both rhodamine
and FITC positive (i.e., immunofluorescence evidence of expression of
both ataxin-1 and ataxin-3) and contained NI of ataxin-1. Small inclusions
formed by wild-type ataxin-1 were defined as those 
 
,
 
2 
 
m
 
m in size, and
large inclusions were 
 
.
 
2 
 
m
 
m. Recruitment of HA-MJD(27) or HA-
MJD(78) into inclusions formed by nuclear targeted NLS-Q27-myc and
NLS-Q78-myc was assessed in a blinded manner and the data were ex-
pressed as the percentage of cells with inclusions in which full-length
ataxin-3 is recruited into inclusions.
 
Results
 
A Pathological Fragment of Ataxin-3 Forms Inclusions 
and Recruits Full-Length Ataxin-3
 
Previously, we demonstrated that a COOH-terminal ataxin-3
fragment containing expanded polyglutamine (HA-Q78)
forms aggregates as detected by immunofluorescence in
transfected cells, whereas full-length expanded ataxin-3,
MJD(78), does not (Paulson et al., 1997
 
b
 
). Moreover, the
aggregates formed by HA-Q78 were biochemically stable
to boiling in SDS and migrated on SDS-polyacrylamide
gels as high molecular weight complexes that remained in
the stacking gel. Coexpression studies suggested that full-
length expanded ataxin-3 could be recruited into both the
immunofluorescent-detectable and SDS-stable complexes,
but this conclusion was based simply on the appearance in
aggregates of immunoreactivity to an NH
 
2
 
-terminal epitope
tag (Paulson et al., 1997
 
b
 
). To confirm that full-length ex-
panded ataxin-3, and not just an NH
 
2
 
-terminal fragment,
was recruited, we carried out similar coexpression studies
Figure 2. Immunofluorescence studies confirm that the full-length disease protein is recruited into aggregates formed by the poly-
glutamine-containing ataxin-3 fragment, HA-Q78. When expressed alone in transfected 293T cells, HA-Q78 forms perinuclear inclu-
sions detectable by anti-HA (c and k). In contrast, full-length mutant ataxin-3 [myc-MJD(78)-F] is diffuse in the cell, detectable with an-
tibodies to epitope tags placed at the NH2 and COOH termini (myc and FLAG, respectively, shown in f and n). When coexpressed with
HA-Q78, full-length mutant ataxin-3 [myc-MJD(78)-F] is efficiently recruited into the inclusions, again detectable with antibodies to
tags at both ends of the protein (h and p show the myc and FLAG staining, respectively). This demonstrates that the full protein, not
simply a proteolytic fragment, is incorporated into polyglutamine inclusions. Background staining in untransfected 293T cells (untx) is
shown for anti-HA (a and i), anti-myc (b), or anti-FLAG (j). 
Perez et al. 
 
Recruitment in Glutamine-Repeat Diseases
 
1461
 
in which both ends of expanded ataxin-3 were epitope-
tagged (myc and FLAG). Doubly tagged ataxin-3 [myc-
MJD(78)-F] was expressed in HEK-293T cells either by
itself or with HA-Q78 (Fig. 2). As shown previously,
HA-Q78 expressed alone formed perinuclear inclusions
(Fig. 2, 
 
c
 
 and 
 
k
 
). Full-length expanded ataxin-3 [MJD(78)]
did not form aggregates, but instead remained diffusely
distributed, primarily in the cytoplasm (Fig. 2, 
 
f
 
 and 
 
n
 
).
However, when coexpressed with HA-Q78, full-length ex-
panded ataxin-3 was efficiently recruited into perinuclear
aggregates seeded by HA-Q78 (Fig. 2, 
 
h
 
 and 
 
p
 
). The re-
cruited protein was detectable with antibodies to both the
NH
 
2
 
- and COOH-terminal epitope tags, suggesting that
full-length protein is efficiently recruited into aggregates.
Recruitment of full-length expanded ataxin-3 was con-
firmed biochemically by immunoblot analysis which showed
that the full protein was recruited into the large SDS-insol-
uble complexes migrating in the stacking gel (Fig. 3).
When expressed by itself, full-length expanded ataxin-3
electrophoresed as monomeric protein (Fig. 3, 
 
b
 
 and 
 
c
 
).
However, when coexpressed with HA-Q78, doubly tagged
ataxin-3 became incorporated into SDS-insoluble com-
plexes detectable with antibodies to either epitope (Fig. 3,
 
b
 
 and 
 
c
 
), again demonstrating that the full protein, not just
a fragment, is recruited into aggregates. Note that only ex-
panded ataxin-3 containing 78 glutamines was recruited
into SDS-insoluble complexes; neither normal ataxin-3
containing 27 glutamines (Fig. 3) nor ataxin-3 lacking a
glutamine repeat (myc-MJD
 
D
 
288-354; not shown) was
recruited into SDS-insoluble complexes, suggesting that
recruitment into SDS-insoluble complexes is dependent
both upon the presence and length of the glutamine re-
peat.
In 293T cells expressing HA-Q78, most inclusions that
form are perinuclear rather than intranuclear. This is con-
sistent with the primarily cytoplasmic expression pattern
of ataxin-3 in transfected 293T cells. To more closely
model the NI found in disease, we targeted expression to
the nucleus by adding a NLS to the COOH-terminal frag-
ment of expanded ataxin-3 (NLS-Q78-myc). Most trans-
fected cells expressing NLS-Q78-myc developed predomi-
nantly NI (Fig. 4 
 
a
 
 and Table I). These NI still readily
recruited ataxin-3 despite the primarily cytoplasmic local-
ization of the full-length protein (Fig. 4, 
 
a
 
 and 
 
b
 
). These
Figure 3. Intact, full-length
expanded ataxin-3 is re-
cruited into SDS-insoluble
polyglutamine aggregates.
Western blots of 293T cells
transfected with the indicated
constructs (above blots) and
probed with anti-HA (a),
anti-myc (b), or anti-FLAG
(c). Blots represent identical
samples run in parallel. (a)
HA-Q78 migrates as a high
molecular weight complex
that remains in the stacking
gel (bracket). On Western
blots, anti-HA also cross-
reacts with a cellular protein
at 35 kD. This protein is not
detected under more native
conditions using immunoflu-
orescence (see Fig. 2 a). (b)
Coexpression of myc-MJD
(78)-F with HA-Q78 leads to
recruitment of the NH2 ter-
minus (myc epitope) of myc-
MJD(78)-F into a high mo-
lecular weight SDS-insoluble
complex in the stacking
gel; myc-MJD(27) is not re-
cruited into an SDS-insoluble
complex. (c) Blots probed
with anti-FLAG demonstrate
that the COOH terminus of
myc-MJD(78)-F is also pres-
ent in the high molecular
weight SDS-insoluble com-
plex. Similar results were ob-
tained when blots were stripped
and sequentially probed with
each antibody.The Journal of Cell Biology, Volume 143, 1998 1462
data, along with data in Fig. 3, are consistent with a model
of disease in which intranuclear aggregates, once initiated,
can recruit full-length ataxin-3.
The fact that ataxin-3 recruitment into SDS-insoluble
complexes requires an expanded glutamine repeat (see
Fig. 3) suggests that polyglutamine is a critical domain in
the recruitment process. We also tested an ataxin-3 con-
struct lacking a glutamine repeat (myc-MJDD288-354) to
address whether other protein domains in ataxin-3 con-
tribute to recruitment. myc-MJDD288-354 encodes the
NH2-terminal 80% of the ataxin-3 polypeptide and is miss-
ing only the glutamine repeat and the subsequent 43
amino acids of the COOH terminus of the protein. When
expressed alone, myc-MJDD288-354 localized diffusely
throughout the cell, but when coexpressed with HA-Q78 it
colocalized to HA-Q78 inclusions detected by immuno-
fluorescence (Fig. 5). However, myc-MJDD288-354 is not
detected in HA-Q78 SDS-insoluble protein complexes
present in stacking gel after gel electrophoresis (not
shown). These results suggest that NH2-terminal regions
of ataxin-3 may interact with the COOH terminus of the
protein where the glutamine repeat resides, but that while
this interaction can be detected under more native condi-
tions of immunofluorescence, it is not stable in the pres-
ence of SDS. One candidate region is a predicted coiledÐ
coil domain just upstream of the glutamine repeat, as
coiledÐcoil domains frequently mediate proteinÐprotein
interactions (Lupas, 1996). Two-hybrid studies have been
initiated recently to examine potential self-association do-
mains of ataxin-3.
Figure 4. Addition of a NLS to the COOH-terminal fragment of mutant ataxin-3 (NLS-Q78-myc) results in the formation of NI in 293T
cells and is capable of redistributing mutant ataxin-3 from a predominately cytoplasmic to nuclear localization. (a) Expression of NLS-
Q78-myc results in nuclear inclusions which are labeled with anti-myc (top). The normally cytoplasmic full-length, expanded repeat
ataxin-3 [HA-MJD(78), middle] is recruited into these nuclear inclusions (bottom). (b) Nuclear inclusions formed by NLS-Q78-myc re-
cruit MJD(27) and MJD(78) more efficiently than NLS-Q27-myc (see Fig. 9 a for inclusions formed by NLS-Q27-myc). Recruitment
was quantified in a blinded manner by counting cotransfected cells with nuclear inclusions in which the ataxin-3 label (anti-HA) colocal-
ized with the inclusions.
Table I. Formation of Nuclear Inclusions by Truncated
Ataxin-3 Containing Normal or Expanded Polyglutamine
and a Nuclear Localization Signal
Construct transfected % transfected cells with NI
NLS-Q27-myc 75% (102/136)
NLS-Q78-myc 82% (86/105)
HEK-293T cells were transfected with the above constructs and the percentage of
transfected cells containing NI was quantified. Data were pooled from four indepen-
dent experiments in which random fields were analyzed. The numbers in parentheses
represent the ratio of inclusion positive cells to the total number of transfected cells
counted.Perez et al. Recruitment in Glutamine-Repeat Diseases 1463
Recruitment of Ataxin-3 into NI Formed by Another 
Polyglutamine-Repeat Disease Protein
The preceding results show that although other regions of
ataxin-3 may participate in recruitment, the glutamine do-
main appears to be an important factor in both formation
and recruitment into aggregates. Therefore, one would
predict that two unrelated glutamine-repeat disease pro-
teins would recruit each other into aggregates. To test this,
we coexpressed ataxin-3 with normal or expanded ataxin-1,
the disease protein in SCA1. Ataxin-1 is a 95-kD nuclear
protein that has no sequence similarity to ataxin-3 outside
of the glutamine repeat, and is not known to interact with
ataxin-3 (Banif et al., 1994). Skinner et al. (1997) demon-
strated previously that full-length ataxin-1 forms NI in
transfected Cos cells. In transfected 293T cells, normal
ataxin-1 [F-SCA1(30)] formed small NI (Fig. 6 a, middle),
whereas expanded ataxin-1 [F-SCA1(82)] formed large
nuclear inclusions (Fig. 6 b, top), confirming the results of
Skinner et al. (1997). When coexpressed with ataxin-1, ex-
panded ataxin-3 [HA-MJD(78)] was recruited into both
the small and large nuclear inclusions formed by normal
and expanded ataxin-1, respectively (Fig. 6, a and b, bot-
tom). The presence of a glutamine repeat seems to be nec-
essary for this recruitment since myc-MJDD288-354 was
not recruited into ataxin-1 nuclear inclusions (not shown).
This result further supports a model in which the poly-
glutamine domain is an important component of recruit-
ment into nuclear aggregates.
Addition of a Glutamine Domain onto GFP Induces 
Recruitment into Aggregates
To directly determine whether a glutamine repeat is suffi-
cient to confer recruitment onto a protein, we performed
coexpression experiments with GFP/polyglutamine fusion
proteins. Using constructs in which GFP is fused to non-
pathologic glutamine repeats of 19 or 35 residues (GFP-
Q19 or GFP-Q35) we assessed recruitment into HA-Q78
inclusions. When expressed alone, unmodified GFP, GFP-
Q19, and GFP-Q35 were diffusely localized in the cell
(Fig. 7, a and b; data not shown for GFP-Q35). However,
when coexpressed with HA-Q78, GFP-Q19 and GFP-Q35
were readily recruited into inclusions (Fig. 7 b, bottom;
data not shown for GFP-Q35), whereas unmodified GFP
was not (Fig. 7 a, bottom).These results demonstrate that a
nonpathologic glutamine repeat is sufficient to confer re-
cruitment onto an otherwise irrelevant protein. Despite
immunofluorescent evidence of GFP-fusion protein re-
cruitment, Western blot analysis showed that GFP-Q19
and GFP-Q35 were not incorporated into the high molec-
ular weight SDS-insoluble complexes formed by HA-Q78
(Fig. 7 c). Fusion of GFP to a long glutamine stretch, GFP-
Q80, leads to the formation of a high molecular weight
SDS-insoluble protein complex similar to that formed by
HA-Q78 (Fig. 7 c). This provides further evidence that re-
cruitment into the SDS-insoluble complexes requires an
expanded glutamine domain.
Recruitment of Normal Cellular Proteins Containing 
Polyglutamine into Nuclear Inclusions
To determine if glutamine-mediated recruitment occurs in
vivo, we carried out immunostaining for a known gluta-
mine-repeat containing protein, EYA, in a recently devel-
oped  Drosophila transgenic model of glutamine-repeat
disease (Warrick et al., 1998). The EYA protein plays an
essential role in Drosophila eye development and contains
a polyglutamine tract near the NH2 terminus (Bonini et
al., 1993). Normally, EYA protein is localized diffusely in
the nucleus (Bonini et al., 1998). However, in fly lines with
NI, EYA is recruited into NI (Fig. 8 a, arrows). Ectopic ex-
pression of an NH2-terminal fragment of EYA containing
the glutamine domain shows that this too is recruited into
NI (Fig. 8 b). However, a COOH-terminal fragment of the
EYA protein lacking the glutamine repeat, but containing
the highly conserved EYA domain, is not recruited into NI
(Fig. 8 c), suggesting that EYA recruitment is dependent
upon the presence of its glutamine repeat. Mammalian
orthologues of the EYA protein lack a glutamine repeat,
Figure 5. Ataxin-3 lacking a glutamine domain is incorporated
into polyglutamine inclusions. Inclusions formed in 293T cells by
HA-Q78 are detected by anti-HA antibody (top). An NH2-termi-
nal fragment of ataxin-3 lacking the glutamine domain, myc-
MJDD288-354, maintains the diffuse localization seen with the
full-length protein (middle). When coexpressed with HA-Q78,
myc-MJDD288-354 becomes redistributed into the inclusions
seeded by HA-Q78 (bottom), suggesting that regions other than
the glutamine domain of ataxin-3 may also play a role in recruit-
ment into inclusions.The Journal of Cell Biology, Volume 143, 1998 1464
and thus it is perhaps not surprising that mammalian EYA
proteins do not localize to NI in SCA3/MJD brain (not
shown).
The results with EYA provide in vivo evidence that an
endogenous polyglutamine-containing protein is recruited
into NI. They support a model of disease in which poly-
glutamine aggregates may cause neuronal dysfunction by
sequestering normal polyglutamine-containing proteins.
In humans, several nuclear proteins contain polyglutamine
tracts or glutamine-rich domains, including several tran-
scription factors. One or more of these proteins might be
recruited into NI in a glutamine-repeatÐdependent man-
ner, thereby reducing total cellular activity or altering
properties of the recruited proteins. TBP, or TFIID, is
an intriguing candidate protein because of its relatively
long polyglutamine tract of 38 residues and its critical role
in transcription. Therefore, we performed immunohisto-
chemistry with anti-TBP antibodies against control and
SCA3/MJD brain tissue. These studies showed that TBP
colocalizes to NI in SCA3/MJD disease brain (Fig. 9). Im-
munostaining of NI was seen with two antibodies against
TBP, one raised against the full protein (Fig. 9 b) and a
second against an NH2-terminal peptide of TBP that does
not contain the glutamine domain (Fig. 9 d). Western blot
of disease brain tissue (Fig. 9 f) and immunofluorescence
analysis of transfected cells showed that neither antibody
cross-reacts with the normal or expanded glutamine do-
mains in ataxin-3 (not shown). Comparative immunostain-
ing of adjacent sections with ataxin-3 antibody indicated
that approximately one-fourth of NI in disease tissue con-
tains TBP; coimmunofluorescence staining of brain tis-
sue with ubiquitin and TBP antisera confirmed that only
a fraction of NI contains TBP. This finding that not all
NI immunostain for TBP is consistent with results from
our laboratory and others showing that NI are hetero-
geneous with respect to size, shape, and molecular com-
position (Cummings et al., 1998; Paulson, H.L., unpub-
lished observations). These results with EYA protein
and TBP are the first to show that recruitment of specific
polyglutamine-containing proteins occurs in vivo.
Nuclear Localization Promotes Aggregate Formation
An intriguing feature of glutamine-repeat diseases is that
despite a primarily cytoplasmic localization for several dis-
ease proteins, the nucleus seems to be the major site of ag-
gregation. Therefore, we sought to determine whether the
nuclear environment per se promotes aggregation. To do
this, we targeted a nonpathologic glutamine repeat to the
nucleus and assessed whether this led to the formation of
Figure 6. Cytoplasmic ataxin-3 is redistributed into NI formed by normal and expanded repeat ataxin-1. (a) FLAG-tagged normal
ataxin-1, SCA1(30), forms small intranuclear structures (middle) which are able to recruit HA-tagged MJD(27) (not shown) and HA-
MJD(78) (bottom). (b) FLAG-tagged expanded repeat ataxin-1, SCA1(82), forms larger NI (top) which also recruit HA-MJD(27) (not
shown) and HA-MJD(78) (bottom).Perez et al. Recruitment in Glutamine-Repeat Diseases 1465
NI. Typically, a COOH-terminal fragment of ataxin-3 con-
taining a repeat of 27 glutamine residues is expressed dif-
fusely in the cell (Paulson et al., 1997b). Adding a NLS to
this ataxin-3 fragment (NLS-Q27-myc) led to intranuclear
localization and formation of NI (Fig. 10 a and Table I).
By immunofluorescence, NLS-Q27-myc inclusions resem-
bled those formed by NLS-Q78-myc. However, two lines
of evidence suggest that they differ in important respects.
First, immunofluorescence analysis showed that NI formed
by NLS-Q27-myc were less efficient at recruiting full-
length ataxin-3 (Fig. 4 b). Second, by Western blot analysis
NLS-Q27-myc did not form the high molecular weight
SDS-insoluble complex regularly observed with NLS-Q78-
myc (Fig. 10 b). The simplest explanation for these differ-
ences is that the intermolecular polyglutamine interactions
in NLS-Q27-myc inclusions differ from those in NLS-Q78-
myc inclusions.
Discussion
Misfolding and aggregation of the disease protein appears
to be central to the pathogenesis of the glutamine-repeat
diseases. In most if not all glutamine-repeat diseases, ag-
gregation is manifested by the formation of NI in suscepti-
Figure 7. A glutamine stretch on the control protein, GFP, is sufficient for recruitment into polyglutamine inclusions but not SDS-insol-
uble protein complexes. Untransfected 293T cells (untx) do not label for anti-HA or GFP (a, top). Expression of GFP (a, third row) or
GFP-Q19 (b, top) alone shows a diffuse staining throughout the cell. However, when coexpressed with HA-Q78, GFP-Q19 becomes re-
distributed into inclusions (b, bottom) whereas GFP itself does not (a, bottom). (c) GFP-Q80 forms a high molecular weight SDS-insolu-
ble protein complex (bracket) when expressed alone, whereas GFP-Q19 and GFP-Q35 do not. When coexpressed with HA-Q78, neither
GFP-Q19 nor GFP-Q35 becomes recruited into the HA-Q78 SDS-insoluble protein complex, showing that recruitment into this com-
plex is dependent on glutamine repeat length.The Journal of Cell Biology, Volume 143, 1998 1466
ble neurons (Davies et al., 1998). The molecular events
driving polyglutamine aggregate formation are still poorly
understood, but a commonly held view is that limited pro-
teolysis may generate aggregation-prone fragments of the
mutant protein in at least some glutamine-repeat diseases
(Goldberg et al., 1996; Ikeda et al., 1996; DiFiglia et al.,
1997; Merry et al., 1998; Wellington et al., 1998). Such
fragments might serve to initiate the formation of aggre-
gates that, once begun, could recruit full-length disease
protein and other cellular proteins containing a glutamine
repeat. In this paper we have provided in vitro and in vivo
evidence supporting such a recruitment model. We have
demonstrated that full-length disease protein is efficiently
recruited into NI seeded by a polyglutamine-containing
fragment, and that certain other glutamine-repeat proteins
localize to NI in human disease tissue and in a transgenic
model. Our results support the general view that poly-
glutamine is a critical domain in the recruitment process,
although in the particular case of ataxin-3, other domains
within the protein also likely contribute to recruitment.
Several lines of evidence presented here suggest that in-
teractions between glutamine repeats play an important
role in recruitment of proteins into NI. First, adding a
glutamine domain to GFP is sufficient to cause recruit-
ment of this otherwise irrelevant protein. This finding
argues strongly for direct polyglutamineÐpolyglutamine
interactions as one important molecular mechanism un-
derlying recruitment into aggregates. Second, recruitment
of EYA in the fly is dependent upon the presence of the
glutamine repeat. Third, recruitment into SDS-insoluble
complexes is dependent upon an expanded glutamine-
repeat within the recruited protein. Finally, the recruit-
ment of TBP in SCA3/MJD brain is consistent with an im-
portant contributory role for the glutamine repeat within
the recruited protein. However, we stress that the ability
of polyglutamine to confer recruitment on a given protein
Figure 8. In vivo recruitment
of EYA in a Drosophila
model of polyglutamine dis-
ease is dependent on the
presence of its glutamine do-
main. The left column rep-
resents sections labeled
with  anti-HA, detecting the
HA-Q78 protein. The mid-
dle column is labeled with
10H6, recognizing a con-
served peptide domain pres-
ent in the expressed EYA
proteins. The first two col-
umns are merged into the
right column. (a) NI (arrows)
formed by truncated ataxin-3
(HA-Q78) are visualized
with anti-HA labeling. Anti-
Eya label demonstrates that
in the transgenic fly express-
ing an expanded glutamine
domain, the endogenous
EYA protein is primarily lo-
calized throughout the nu-
cleus and in many cells has a
distinct punctate appear-
ance. The overlay indicates
that the EYA protein colo-
calizes with polyglutamine in-
clusions. (b) Ectopic expres-
sion of the NH2-terminal half
of the EYA protein, which
contains the polyglutamine
repeat. Coexpression of the
HA-Q78 protein with the
EYA NH2 terminus shows
that EYA containing the
glutamine domain is concentrated in the NI (arrow). (c) Ectopic expression of the COOH-terminal half of the EYA protein, which con-
tains the highly conserved Eya domain, but not the glutamine repeat. Coexpression of the HA-Q78 protein (arrow) with the EYA
COOH-terminal domain shows that the COOH-terminal domain lacking the glutamine repeat does not become recruited into NI. Pho-
tographs in a are from the developing eye field of an eye-antennal imaginal disc from a third-instar larva expressing HA-Q78 with gmr-
GAL4; those in b and c are from the antennal field of developing eye-antennal imaginal discs of larvae expressing HA-Q78 and the eya
constructs with dpp-GAL4.Perez et al. Recruitment in Glutamine-Repeat Diseases 1467
likely varies depending upon its particular protein and cel-
lular context. The results with TBP illustrate this point:
TBP recruitment is seen in only a fraction of NI in SCA3/
MJD brain, suggesting that the presence of a glutamine re-
peat is not always sufficient to confer recruitment. Based
on our results, we anticipate that some but not all glu-
tamine-repeat proteins will be recruited into NI; it will be
important to determine if additional polyglutamine pro-
teins are recruited into aggregates both in vivo and in
vitro. It is also important to stress that clearly not all pro-
teins colocalizing to NI are recruited by virtue of their hav-
ing a glutamine repeat. For example, the colocalization of
proteasome and chaperone proteins to NI instead likely
reflects the inherent functions of these proteins (Cum-
mings et al., 1998; Paulson, H.L., unpublished observa-
tion).
Our results with EYA and TBP represent the first in
vivo evidence that nondisease glutamine repeat proteins
are sequestered within NI, raising the possibility that the
neuronal toxicity of glutamine-repeat diseases may in part
result from sequestration of other polyglutamine-contain-
ing proteins within aggregates. Given that only a subset
of inclusion-positive neurons show TBP recruitment, our
data suggest that the presence of a polyglutamine tract fa-
vors but is not itself sufficient to cause recruitment into NI.
The sequestering of polyglutamine-containing transcrip-
tion factors might perturb transcriptional events with po-
tentially adverse effects for the neuron (Gerber et al.,
1994). It will be important to determine if recruitment of
other polyglutamine-containing nuclear factors occurs and
to extend our results to other glutamine-repeat diseases. A
complete account of all the proteins comprising NI awaits
the purification and dissociation of NI into constituent
proteins, a challenging task now being pursued by several
laboratories.
A controversial and unresolved issue is whether aggre-
gate formation is initiated by the full-length protein or a
polyglutamine-containing fragment of the disease protein.
The answer, in fact, may differ depending upon the dis-
ease. In SCA1, for example, evidence suggests that full-
length ataxin-1 is responsible for aggregate formation
(Burright et al., 1995; Skinner et al., 1997), whereas in
HuntingtonÕs disease evidence is consistent with proteoly-
sis playing a role in aggregate formation (Goldberg et at.,
1996; DiFiglia et al., 1997; Davies et al., 1998). Regardless
of which is the case for SCA3/MJD, our results indicate
that once aggregation is initiated, the full-length protein
can be recruited efficiently into aggregates. In the human
disease state, similar sequestering of the disease protein
could contribute to pathogenesis by reducing cellular lev-
els of functional ataxin-3. If this occurs, then the disease
process would reflect not only the well-accepted dominant
toxic gain-of-function, but also a partial loss-of-function of
the disease protein. Since the function of ataxin-3 is un-
known, it is not currently possible to test this hypothesis in
SCA3/MJD. However, clinical features and in vitro studies
in another glutamine-repeat disease, spinobulbar muscular
atrophy, are consistent with a partial loss-of-function of
the disease protein, the androgen receptor (reviewed in
Merry and Fischbeck, 1998).
Our finding that a fragment of normal ataxin-3 with 27
glutamines forms inclusions only when targeted to the nu-
cleus strongly supports a proaggregatory role for the nu-
cleus. Recent studies of SCA1 transgenic mice further sug-
Figure 9. TBP immunoreactivity in NI
in SCA3/MJD disease brain. Sections
from control and disease pons were im-
munohistochemically stained with two
different anti-TBP antisera or antiÐ
ataxin-3 antiserum. (a) AntiÐataxin-3
immunostains NI within neurons of
SCA3/MJD brain. (b) An adjacent sec-
tion stained with the anti-TBP anti-
body SI-1 demonstrates TBP present
within a subset of NI. (c) Control brain
immunolabeled with SI-1. (d) Higher
power magnification of SCA3/MJD
pons showing immunolabeling of a NI
with a second anti-TBP antibody, N-12.
(e) Control brain immunolabeled with
N-12. (f) Western blot of lysate from
SCA3/MJD pons probed with the anti-
TBP antibody N-12 (lane 1) or ataxin-3
antisera (lane 2) confirms the specific-
ity of the TBP antibody. Arrows in a, b,
and  d indicate neurons that have NI.
Original magnification, 3630 (aÐc) and
31,260 (d and e). The arrow indicates
TBP in lane 1 and arrowheads indicate
ataxin-3 protein from normal and ex-
panded alleles in lane 2.The Journal of Cell Biology, Volume 143, 1998 1468
gest this is true in vivo as well: mutant ataxin-1 that has
been modified to stay in the cytoplasm no longer forms ag-
gregates (Klement et al., 1998). Aggregation may occur
preferentially in the nucleus for one or more reasons. The
nuclear and cytoplasmic compartments may differ funda-
mentally in their capacity to handle misfolded polypep-
tides perhaps in part due to differences in their comple-
ment of chaperonins and proteasomes (Michels et al.,
1997). Alternatively, the cytoarchitecture of the nucleus
could lead to higher focal concentrations of disease pro-
tein that would accelerate aggregate formation. Subnu-
clear domains exist that may serve as sites for expanded
glutamine disease protein to accumulate and aggregate
(Skinner et al., 1997; Lamond and Earnshaw, 1998). Lastly,
since the protein composition differs between the nucleus
and the cytoplasm, interactions with selective nuclear pro-
teins may render polyglutamine prone to aggregation.
If, as we have shown, an ataxin-3 fragment with a non-
pathologic glutamine repeat will aggregate when targeted
to the nucleus, what prevents NI from forming in the ab-
sence of glutamine-repeat expansion? The simplest expla-
nation for this result is that even a normal glutamine re-
peat of 27 residues has a low probability of misfolding and
aggregating, and that by freeing this repeat from its nor-
mal protein context, forcing it into the nucleus and overex-
pressing it in transfected cells, we are effectively driving
this misfolding and aggregation. It is clear that the inter-
molecular interactions within NLS-Q27 inclusions differ
from those within NLS-Q78 inclusions, since NLS-Q27 in-
clusions do not efficiently recruit full-length ataxin-3 and
do not form the high molecular weight SDS-insoluble
complexes seen with the expanded glutamine domain. Al-
though NI can form from nonpathological glutamine do-
mains when overexpressed in vitro, in vivo there may be
protective mechanisms which can dissociate these weaker
aggregates if they are formed (Glover and Lindquist,
1998). This cellular paradigm provides a model to further
characterize the nature of nuclear aggregation and to iden-
tify specific proaggregatory nuclear factors.
Two recent studies further support a role for the nucleus
in the pathogenesis of glutamine-repeat diseases. In SCA1
transgenic mice, mutant ataxin-1 protein lacking a NLS re-
mains in the cytoplasm, fails to aggregate, and does not
cause neurodegeneration (Klement et al., 1998). In an in
vitro model of HuntingtonÕs disease, mutant huntingtin
modified with a nuclear export signal no longer forms ag-
gregates or induces apoptotic cell death (Saudou et al.,
1998). These same studies also demonstrate that observ-
able NI are not necessary for the onset of pathogenesis in
mice or for the induction of apoptosis in cultured neurons.
These studies thus raise the question, What role if any do
NI play in the glutamine-repeat disease process? We favor
the view that in this group of chronic neurodegenerative
disorders, disease progression is complex, consisting of at
Figure 10. Expression of a nonpatho-
logic glutamine stretch in the nucleus
leads to formation of nuclear inclusions
but not SDS-insoluble complexes in
293T cells. (a) Nuclear localization of a
COOH-terminal fragment of ataxin-3
containing 27 glutamines (NLS-Q27-
myc) leads to the formation of NI de-
tected by anti-myc epitope tag. Un-
transfected cells (untx) are not labeled
with anti-myc. (b) Western blot of 293T
cells transfected with a COOH-ter-
minal fragment of ataxin-3 containing
27 glutamines (NLS-Q27-myc) or 78
glutamines (NLS-Q78-myc) targeted to
the nucleus. Anti-myc labeling shows
that NLS-Q27-myc forms a major band
at 25 kD, whereas NLS-Q78-myc forms
a 40-kD band as well as a high molecu-
lar weight, SDS-insoluble complex
which remains in the stacking gel
(bracket).Perez et al. Recruitment in Glutamine-Repeat Diseases 1469
least two stages: an early period of neuronal dysfunction
and a later period of exacerbated dysfunction and neu-
ronal demise. Although early neuronal dysfunction proba-
bly is a direct consequence of misfolding of the disease
protein, observable aggregates may not be necessary. At
early points in pathogenesis, one possibility is that ex-
panded polyglutamine alters proteinÐprotein interactions
subtly in a disease- and neuron-specific manner, resulting
in abnormal neuronal function. In later stages of disease,
however, when NI are clearly detectable in pathologic
studies, we propose that NI contribute to exacerbated dys-
function and neuronal demise. The findings described in
this report do not implicate NI in neuronal demise di-
rectly, but suggest ways that these structures might perturb
normal nuclear events, including the sequestering of nu-
clear proteins that contain glutamine repeats or gluta-
mine-rich domains. Clearly, further studies of cellular and
animal models are necessary to determine the precise role
of NI in later stages of disease.
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